Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 16/20 | 0.75 |
| ▸ | ATM | Q13315 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | TAF1 | P21675 | 1/20 | 0.50 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16416734 | 0.86 | BRD4 (1.00) | BRD4ATMTAF1TAF1L | |
| SCHEMBL16416690 | 0.84 | BRD4 (1.00) | BRD4NPC1RAB9A | |
| SCHEMBL17833793 | 0.83 | BRD4 (0.75) | BRD4TAF1TAF1L | |
| SCHEMBL17833794 | 0.83 | BRD4 (0.72) | BRD4TAF1TAF1L | |
| SCHEMBL6747493 | 0.82 | ATM (0.65) | BRD4ATMNPC1RAB9A | |
| SCHEMBL16424682 | 0.81 | BRD4 (1.00) | BRD4TAF1TAF1L | |
| SCHEMBL16416674 | 0.81 | BRD4 (0.81) | BRD4TAF1TAF1L | |
| SCHEMBL17833799 | 0.81 | BRD4 (0.74) | BRD4TAF1TAF1L | |
| SCHEMBL2992163 | 0.80 | KDM4E (0.64) | BRD4ATMNPC1RAB9A | |
| SCHEMBL17833815 | 0.80 | BRD4 (0.89) | BRD4TAF1TAF1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-9975896-B2 | Inhibitors of transcription factors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20160168154-A1 | INHIBITORS OF TRANSCRIPTION FACTORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168154-A1 | INHIBITORS OF TRANSCRIPTION FACTORS AND USES THEREOF | BRD4, BRPF3, EP300 | BRD4 1/4885ATM 2269/4885NPC1 1862/4885 |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | BRD4 205/4885ATM 304/4885NPC1 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.